Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients
Erwin Krikken(University Medical Center Utrecht), Jannie P. Wijnen(University Medical Center Utrecht), Hanneke W.M. van Laarhoven(Dutch Cancer Society), P. J. van Diest(University Medical Center Utrecht), Moritz Zaiß(Friedrich-Alexander-Universität Erlangen-Nürnberg), Rajni A. Jibodh(Amsterdam UMC Location University of Amsterdam), Dennis W. J. Klomp(University Medical Center Utrecht), Vitaliy Khlebnikov(University Medical Center Utrecht), Peter R. Luijten(University Medical Center Utrecht)
Cited by 55
Related Papers
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|The Lancet. Gastroenterology & hepatology|2019|597
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Pros and cons of ultra-high-field MRI/MRS for human application
|Progress in Nuclear Magnetic Resonance Spectroscopy|2018|542